$SPRB News

Spruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst Conference

Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual Meeting

Citizens Reiterates Market Outperform on Spruce Biosciences, Maintains $144 Price Target

Lake Street Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $149

Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Spruce Biosciences stock gains after analyst backs regulatory progress

Spruce Biosciences Announces Launch of MPS3BStudy.com

Spruce Biosciences Launches MPS3BStudy.com, Online Resource For Families And Caregivers Of Children With Sanfilippo Syndrome Type B

Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026

Guggenheim Maintains Buy on Spruce Biosciences, Lowers Price Target to $104

Citizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $144

Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences

SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. Q2 EPS $(6.68) Misses $(5.80) Estimate

Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development

Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer

B. Riley Securities Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $160

Spruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit

Spruce Biosciences Possibly First In-MPS IIIB Class Enzyme Replacement Therapy

Spruce Biosciences Joins the Russell 3000® Index